Company news

Verastem, Inc. news in 2023

Verastem, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

December 17, 2023

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

December 12, 2023

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

November 12, 2023

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 7, 2023

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

November 6, 2023

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

November 5, 2023

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

October 25, 2023

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

October 13, 2023

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

September 27, 2023

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

August 27, 2023

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 7, 2023

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

July 10, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

July 4, 2023

Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants

June 15, 2023

Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 14, 2023

Verastem Oncology Announces Reverse Stock Split

May 30, 2023

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

May 24, 2023

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

May 15, 2023

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 8, 2023

New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

April 25, 2023

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

April 17, 2023

New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

March 14, 2023

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

March 13, 2023

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

February 1, 2023

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

January 23, 2023

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

January 23, 2023

Decks in 2023